A biodegradable injectable thermoplastic for localized camptothecin delivery

Hatefi, Arash; Knight, Darryl K.; Amsden, Brian G.

doi:10.1002/jps.20045

Cited by 21 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6. As has been found in previous work [12] the degradation of the OCL proceeded slowly, with only a decrease in mass of 12% attained over the 12-week period. The apparently faster degradation rate at the first time point is attributed to particulate losses during the removal of the aqueous media from the vials.…”

Section: Resultssupporting

confidence: 55%

“…Moreover, it was reasoned that a thermoplastic delivery vehicle would be simple and easy to administer. We therefore examined the use of oligo(ε-caprolactone) as a delivery vehicle for long-term local delivery of camptothecin [12] and demonstrated that the melt viscosity of this vehicle can be manipulated by the choice of initiator used in preparing the oligomer [13]. Although camptothecin could be delivered in its active lactone form for more than 90 days, the oligomers did not degrade appreciably in vitro over that time period.…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Preparation and characterization of blends of star-poly(ε-caprolactone-co-D,L-lactide) and oligo(ε-caprolactone)

Tomkins¹,

Kontopoulou²,

Amsden³

2005

Journal of Biomaterials Science, Polymer Edition

Self Cite

View full text Add to dashboard Cite

Polymer blending provides a relatively facile means of combining the separate desirable properties of different polymers into a single material. In this paper blends of a low-molecular-weight star co-polymer of epsilon-caprolactone and D,L-lactide with a linear oligo(epsilon-caprolactone) are prepared and characterized as a possible biodegradable injectable drug-delivery vehicle. The melting characteristics, melt viscosity and degree of crystallinity of the blends were measured, and an in vitro degradation study was performed over a period of 12 weeks. The blends all had a single glass transition temperature and an onset of melting point near body temperature, with the melting point range decreasing as the star co-polymer content increased. The melt viscosity of the blends increased as the star co-polymer content increased, in a manner consistent with miscible blend behavior. The star co-polymer degraded fastest, with a more than 60% mass decrease over the 12-week period. As the oligo(epsilon-caprolactone) content increased, the degradation rate decreased, with the oligo(epsilon-caprolactone) exhibiting a mass loss of only 12% over the 12-week period.

show abstract

Section: Resultssupporting

confidence: 55%

Section: Introductionmentioning

confidence: 98%

Preparation and characterization of blends of star-poly(ε-caprolactone-co-D,L-lactide) and oligo(ε-caprolactone)

Tomkins¹,

Kontopoulou²,

Amsden³

2005

Journal of Biomaterials Science, Polymer Edition

Self Cite

View full text Add to dashboard Cite

show abstract

“…The development of formulations suitable for cancer chemotherapy is challenged by two key issues: i) anticancer drugs are quite hydrophobic/labile and require solubilizing/ stabilizing strategies to reach efficient concentration into the tumor site; ii) their cytotoxicity demands a local/target delivery to optimize the efficiency/safety ratio [1][2][3]. Several drug delivery systems and administration strategies have been under study in the last two decades for cancer chemotherapy [4,5].…”

Section: Introductionmentioning

confidence: 99%

PEO-PPO Block Copolymers for Passive Micellar Targeting and Overcoming Multidrug Resistance in Cancer Therapy

Alvarez‐Lorenzo

Sosnik²,

Concheiro

2011

CDT

120

View full text Add to dashboard Cite

Drug carriers tailored to fit the physicochemical properties of anticancer agents and the therapeutic peculiarities of tumor management are envisioned for improving the effectiveness/toxicity ratio of the current treatments. Polymeric micelles are attracting much attention owing to their unique beneficial features: i) core-shell structure capable to host hydrophobic drugs, raising the apparent solubility in aqueous medium; ii) size adequate for a preferential accumulation (passive targeting) within the tumor, exhibiting enhanced permeability and retention (EPR effect), and iii) unimers that modulate the activity of efflux pumps involved in multidrug resistance (MDR). This review focuses on amphiphilic poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO) block copolymers, namely the linear poloxamers (Pluronic® or Lutrol®) and the X-shaped poloxamines (Tetronic®), as components of polymeric micelles able to play these three roles. Specific facets of poloxamers have been highlighted some years ago, but recently their wide range of possibilities is beginning to be fully elucidated and understood. Poloxamines are new excipients in the cancer arena and the comparison of their performance with that of poloxamers may enable to identify aspects of their architecture relevant for the optimization of micellar carriers. Clinical trials in progress indicate that drug-loaded polymeric micelles are beneficial regarding efficiency, safety, and compliance of the treatment and quality of life of the patients. The fact that some copolymers are already approved for internal use and several chemotherapy agents will be off patent soon may help to bring the clinical use of poloxamer- or poloxamine-based micelles into a reality in the coming years.

show abstract

“…Moreover, camptothecin requires a prolonged schedule of administration and drug targeting to expand its efficacy [10] .…”

Section: Introductionmentioning

confidence: 99%

Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion

Huang

Hua

Yang³

et al. 2008

Acta Pharmacologica Sinica

180

View full text Add to dashboard Cite

Aim: Camptothecin is an anticancer drug that acts against a broad spectrum of tumors. The clinical application of camptothecin is limited by its insolubility, instability, and toxicity problems. The aim of this study was to develop and characterize lipid nanoparticles with different lipid cores which can circumvent these problems. Methods: Lipid nanoparticles made of Precirol (solid lipid nanoparticles; SLN-P), Compritol (SLN-C), Precirol+squalene (nanostructured lipid carriers; NLC), and squalene (a lipid emulsion; LE) as the lipid core material were prepared. These systems were assessed and compared by evaluating the mean diameter, surface charge, molecular environment, camptothecin release, and cell viability against a melanoma. The safety and storage stability of these systems were also preliminarily examined. Results: The particle size ranged from 190 to 310 nm, with the NLC and LE showing the smallest and largest sizes, respectively. The in vitro drug release occurred in a sustained manner in decreasing order as follows: LE>NLC>SLN-P>SLN-C. It was found that varying the type of inner phase had profound effects on cell viability. The SLN-P generally showed higher cytotoxicity than the free control. The treatment of melanomas with the camptothecin-loaded SLN-C and NLC yielded cytotoxicity comparable to that of the free form. The percentage of erythrocyte hemolysis by all nanoparticles was ≤5%, suggesting a good tolerance to lipid nanoparticles. Conclusion: The results collectively suggest that the SLN-P may have the potential to serve as a delivery system for parenteral camptothecin administration because of the sustained drug release, strong cytotoxicity, limited hemolysis, and good storage stability. Key wordscamptothecin; solid lipid nanoparticle; nanostructured lipid carrier; lipid emulsion; drug delivery; melanoma 4 Correspondence to Prof Jia-you FANG.Phn 886-3-211-8800, ext 5521.

show abstract

A biodegradable injectable thermoplastic for localized camptothecin delivery

Cited by 21 publications

References 22 publications

Preparation and characterization of blends of star-poly(ε-caprolactone-co-D,L-lactide) and oligo(ε-caprolactone)

Preparation and characterization of blends of star-poly(ε-caprolactone-co-D,L-lactide) and oligo(ε-caprolactone)

PEO-PPO Block Copolymers for Passive Micellar Targeting and Overcoming Multidrug Resistance in Cancer Therapy

Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion

Contact Info

Product

Resources

About